India's Ranbaxy eyes French generics mart

12 January 2001

Leading Indian drugmaker Ranbaxy Laboratories is seeking to acquire acompany in the French generic drugs sector, as part of its international expansion plans. It already has strong business operations in Germany and the UK, and last year set up a joint venture in Brazil (Marketletter August 7, 2000). According to India Infoline, Ranbaxy expects to achieve overseas sales of some $1 billion by 2004.

The Indian news service noted that Ranbaxy is gearing up to launch products in 12 European countries, and will introduce generic versions of SmithKline Beecham's (now GlaxoSmithKline) Augmentin (co-amoxiclav) and Aventis' Tarivid (ofloxacin), noting that the patent on the former has already expired in Germany and the UK and will do so in France in 2002.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.